---
figid: PMC4676894__12943_2015_474_Fig9_HTML
figlink: /pmc/articles/PMC4676894/figure/Fig9/
number: Fig. 9
caption: 'Mechanism-based combinatorial experimental regimens aimed at disrupting
  known oncogenic cooperation pathways in ABC-DLBCLs. Targets for rational mechanism-based
  combinatorial experimental regimens are shown for ABC-DLBCL (a and b). The black
  thick lines connecting the different drug targets pathways depict established biological
  interactions and/or dependencies. The single drugs listed in (a) have either proven
  clinical activity in patients with DLBCL or are currently in clinical trials for
  patients with B-cell lymphoma, including DLBCL. Pathways in ABC-DLBCL targeted by
  rational drug combinations using drugs tested as single agent in preclinical studies
  or clinical trials are shown in (b). Bortezomib and carfilzomib inhibit the 26S
  proteasome complex thereby blocking the degradation of negative regulators of cell
  cycle progression as well as of NF-κB inhibitory protein IκBα. Lenalidomide is an
  immunomodulatory agent directly binding to the E3 ubiquitin ligase substrate receptor
  CRBN and promoting the recruitment of its common substrates to the E3 ubiquitin
  ligase complex, thus leading to substrate ubiquitinylation and degradation [] and
  subsequent repression of IRF4, a hallmark of ABC-DLBCL cells, thereby inhibiting
  the BCR-mediated canonical NF-κB-dependent pro-survival signaling pathways [, ].
  Silvestrol inhibits RNA helicase and translation initiationfactor eIF4A thereby
  blocking translation (i.e., of oncogenic factors) []. Azacytidine (AZA) and decitabine/5-aza-2′-deoxycytidine
  (DAC/5-AZA) inhibit DNA methyltransferases (mainly DMNT1 and DMNT3) resulting in
  the re-expression of tumor-suppressor genes [, ]. Mechanism-based drug combinations
  targeting the biological interaction between MYC and BCL2 as well as MYC and the
  PI3K/AKT/mTORC1 pathway are aimed for both GCB- and ABC-DLBCL. Adapted from REF:
  [, ]. Information for this figure was gleaned from the following references: [,
  , , –, , , , , , , , , –, , , , , –, , , , , , , , , , , –, , , , , , , , , , ,
  –, –, , , , , , –, , , , , –, –, , , , –, , –, , , , , –]. See also Additional file
  : Table S2 and S5–S9. Abbreviations: BCR B cell receptor, BTK Bruton’s tyrosine
  kinase, CD40L CD40 ligand, JAK Janus kinase, CRBN cereblon, IRF4 interferon-regulatory
  factor 4, MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein
  1, BCL10 B cell lymphoma protein 10, TLR Toll-like receptor, MyD88 myeloid differentiation
  primary response 88, CARD11 caspase recruitment domain family, member 11, PKCβ protein
  kinase Cβ, IKK inhibitor kappa B (IκB) kinase, NF-κB nuclear factor-kappa B, NIK
  NF-κB inducing kinase, STAT signal transducer and activator of transcription, PI3K
  phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1,
  BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, TGFβR transforming
  growth factor beta (TGFβ) receptor, HDACi inhibitors of histone deacetylases, BCL6i
  inhibitors of BCL6, PD-1 programmed cell death, PD-L1 programmed cell death ligand,
  AZA azacytidine, DAC decitabine'
pmcid: PMC4676894
papertitle: 'Novel drug targets for personalized precision medicine in relapsed/refractory
  diffuse large B-cell lymphoma: a comprehensive review.'
reftext: Rosalba Camicia, et al. Mol Cancer. 2015;14:207.
pmc_ranked_result_index: '233791'
pathway_score: 0.5048307
filename: 12943_2015_474_Fig9_HTML.jpg
figtitle: Mechanism-based combinatorial experimental regimens aimed at disrupting
  known oncogenic cooperation pathways in ABC-DLBCLs
year: '2015'
organisms: Homo sapiens
ndex: 40328fa7-df29-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4676894__12943_2015_474_Fig9_HTML.html
  '@type': Dataset
  description: 'Mechanism-based combinatorial experimental regimens aimed at disrupting
    known oncogenic cooperation pathways in ABC-DLBCLs. Targets for rational mechanism-based
    combinatorial experimental regimens are shown for ABC-DLBCL (a and b). The black
    thick lines connecting the different drug targets pathways depict established
    biological interactions and/or dependencies. The single drugs listed in (a) have
    either proven clinical activity in patients with DLBCL or are currently in clinical
    trials for patients with B-cell lymphoma, including DLBCL. Pathways in ABC-DLBCL
    targeted by rational drug combinations using drugs tested as single agent in preclinical
    studies or clinical trials are shown in (b). Bortezomib and carfilzomib inhibit
    the 26S proteasome complex thereby blocking the degradation of negative regulators
    of cell cycle progression as well as of NF-κB inhibitory protein IκBα. Lenalidomide
    is an immunomodulatory agent directly binding to the E3 ubiquitin ligase substrate
    receptor CRBN and promoting the recruitment of its common substrates to the E3
    ubiquitin ligase complex, thus leading to substrate ubiquitinylation and degradation
    [] and subsequent repression of IRF4, a hallmark of ABC-DLBCL cells, thereby inhibiting
    the BCR-mediated canonical NF-κB-dependent pro-survival signaling pathways [,
    ]. Silvestrol inhibits RNA helicase and translation initiationfactor eIF4A thereby
    blocking translation (i.e., of oncogenic factors) []. Azacytidine (AZA) and decitabine/5-aza-2′-deoxycytidine
    (DAC/5-AZA) inhibit DNA methyltransferases (mainly DMNT1 and DMNT3) resulting
    in the re-expression of tumor-suppressor genes [, ]. Mechanism-based drug combinations
    targeting the biological interaction between MYC and BCL2 as well as MYC and the
    PI3K/AKT/mTORC1 pathway are aimed for both GCB- and ABC-DLBCL. Adapted from REF:
    [, ]. Information for this figure was gleaned from the following references: [,
    , , –, , , , , , , , , –, , , , , –, , , , , , , , , , , –, , , , , , , , , ,
    , –, –, , , , , , –, , , , , –, –, , , , –, , –, , , , , –]. See also Additional
    file : Table S2 and S5–S9. Abbreviations: BCR B cell receptor, BTK Bruton’s tyrosine
    kinase, CD40L CD40 ligand, JAK Janus kinase, CRBN cereblon, IRF4 interferon-regulatory
    factor 4, MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein
    1, BCL10 B cell lymphoma protein 10, TLR Toll-like receptor, MyD88 myeloid differentiation
    primary response 88, CARD11 caspase recruitment domain family, member 11, PKCβ
    protein kinase Cβ, IKK inhibitor kappa B (IκB) kinase, NF-κB nuclear factor-kappa
    B, NIK NF-κB inducing kinase, STAT signal transducer and activator of transcription,
    PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex
    1, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, TGFβR transforming
    growth factor beta (TGFβ) receptor, HDACi inhibitors of histone deacetylases,
    BCL6i inhibitors of BCL6, PD-1 programmed cell death, PD-L1 programmed cell death
    ligand, AZA azacytidine, DAC decitabine'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - HDAC8
  - IFNA2
  - IFNA6
  - HDAC1
  - HDAC2
  - IFNA17
  - IFNA21
  - CHUK
  - IKBKB
  - AKT3
  - IFNA4
  - IFNA5
  - SMAD2
  - IFNA7
  - BCL6
  - BCR
  - RPTOR
  - MYC
  - MYD88
  - RELB
  - NFKB1
  - NFKB2
  - REL
  - AKT1
  - AKT2
  - BCL10
  - BCL2
  - CD40
  - AADAC
  - SMAD1
  - SMAD5
  - STAT3
  - HDAC3
  - IFNA8
  - IFNA1
  - TGFB1
  - TGFB2
  - TGFB3
  - SMAD7
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - SMAD6
  - SMAD9
  - TGFBR1
  - TGFBR2
  - TGFBR3
  - IKBKG
  - IRAK4
  - IRF4
  - JAK1
  - JAK2
  - MTOR
  - PTEN
  - PIK3R6
  - PIK3R5
  - PIK3R4
  - CARD11
  - SYK
  - RELA
  - PIK3R3
  - TNFRSF8
  - PIK3CA
  - PRKCB
  - PIK3CB
  - SMAD3
  - SMAD4
  - PDCD1
  - CD274
  - PIK3CD
  - PIK3CG
  - Temsirolimus
  - Enzastaurin
  - Fostamatinib
  - Carfilzomib
  - MK-2206 H
  - PBS-1086 H IKB
  - Cancer
genes:
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC8
  entrez: '55869'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA2
  entrez: '3440'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA6
  entrez: '3443'
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC1
  entrez: '3065'
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC2
  entrez: '3066'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA17
  entrez: '3451'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA21
  entrez: '3452'
- word: IKK/NIK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: CHUK
  entrez: '1147'
- word: IKK/NIK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKB
  entrez: '3551'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA4
  entrez: '3441'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA5
  entrez: '3442'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD2
  entrez: '4087'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA7
  entrez: '3444'
- word: BCL6
  symbol: BCL6
  source: hgnc_symbol
  hgnc_symbol: BCL6
  entrez: '604'
- word: BCR
  symbol: BCR
  source: hgnc_symbol
  hgnc_symbol: BCR
  entrez: '613'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: -Myc
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: MYD88
  symbol: MYD88
  source: hgnc_symbol
  hgnc_symbol: MYD88
  entrez: '4615'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: BCL10
  symbol: BCL10
  source: hgnc_symbol
  hgnc_symbol: BCL10
  entrez: '8915'
- word: BCL2
  symbol: BCL2
  source: hgnc_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: CD40
  symbol: CD40
  source: hgnc_symbol
  hgnc_symbol: CD40
  entrez: '958'
- word: C-Myc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: DAC
  symbol: DAC
  source: hgnc_alias_symbol
  hgnc_symbol: AADAC
  entrez: '13'
- word: SMAD1
  symbol: SMAD1
  source: hgnc_symbol
  hgnc_symbol: SMAD1
  entrez: '4086'
- word: SMAD5
  symbol: SMAD5
  source: hgnc_symbol
  hgnc_symbol: SMAD5
  entrez: '4090'
- word: STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: HDACI
  symbol: HDAC_I
  source: bioentities_symbol
  hgnc_symbol: HDAC3
  entrez: '8841'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA8
  entrez: '3445'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA1
  entrez: '3439'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB1
  entrez: '7040'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB2
  entrez: '7042'
- word: TGFB
  symbol: TGFB
  source: bioentities_symbol
  hgnc_symbol: TGFB3
  entrez: '7043'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD7
  entrez: '4092'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD1
  entrez: '4086'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA10
  entrez: '3446'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA13
  entrez: '3447'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA14
  entrez: '3448'
- word: IFNa/ß
  symbol: IFNA
  source: bioentities_symbol
  hgnc_symbol: IFNA16
  entrez: '3449'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD6
  entrez: '4091'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD9
  entrez: '4093'
- word: TGFBR/SMAD
  symbol: TGFBR
  source: bioentities_symbol
  hgnc_symbol: TGFBR1
  entrez: '7046'
- word: TGFBR/SMAD
  symbol: TGFBR
  source: bioentities_symbol
  hgnc_symbol: TGFBR2
  entrez: '7048'
- word: TGFBR/SMAD
  symbol: TGFBR
  source: bioentities_symbol
  hgnc_symbol: TGFBR3
  entrez: '7049'
- word: IKK/NIK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKG
  entrez: '8517'
- word: IRAK4
  symbol: IRAK4
  source: hgnc_symbol
  hgnc_symbol: IRAK4
  entrez: '51135'
- word: IRF4
  symbol: IRF4
  source: hgnc_symbol
  hgnc_symbol: IRF4
  entrez: '3662'
- word: JAK1/2
  symbol: JAK1
  source: hgnc_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK1/2
  symbol: JAK2
  source: hgnc_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PTEN--
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: RelB/p52
  symbol: RELB
  source: hgnc_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: CARD11
  symbol: CARD11
  source: hgnc_symbol
  hgnc_symbol: CARD11
  entrez: '84433'
- word: SYK
  symbol: SYK
  source: hgnc_symbol
  hgnc_symbol: SYK
  entrez: '6850'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: CD30/BR3
  symbol: CD30
  source: hgnc_prev_symbol
  hgnc_symbol: TNFRSF8
  entrez: '943'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PKCB
  symbol: PKCB
  source: hgnc_prev_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD3
  entrez: '4088'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: TGFBR/SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD5
  entrez: '4090'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K/AKT/MTORC1
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Enzastaurin
  source: MESH
  identifier: C504878
- word: Fostamatinib
  source: MESH
  identifier: C523665
- word: Carfilzomib
  source: MESH
  identifier: C524865
- word: MK-2206 H
  source: MESH
  identifier: C548887
- word: PBS-1086 H IKB
  source: MESH
  identifier: C579556
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
